MocroftA, LundgrenJD, RossM, FuxCA, ReissP, MoranneO, et al.; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study: Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study. Lancet HIV3: e23–e32, 2016PubMed
MocroftA, LundgrenJD, RossM, FuxCA, ReissP, MoranneO, ; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study: Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study. Lancet HIV 3: e23–e32, 2016PubMed)| false
GuaraldiG, MalagoliA, CalcagnoA, MussiC, CelesiaBM, CarliF, et al.: The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: A cross sectional study of people aged 65–74 years and more than 75 years. BMC Geriatr18: 99, 2018PubMed
GuaraldiG, MalagoliA, CalcagnoA, MussiC, CelesiaBM, CarliF, : The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: A cross sectional study of people aged 65–74 years and more than 75 years. BMC Geriatr 18: 99, 2018PubMed)| false
MocroftA, LundgrenJD, RossM, LawM, ReissP, KirkO, et al.; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group: Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med12: e1001809, 2015PubMed
MocroftA, LundgrenJD, RossM, LawM, ReissP, KirkO, ; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group: Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med 12: e1001809, 2015PubMed)| false
SwanepoelCR, AttaMG, D’AgatiVD, EstrellaMM, FogoAB, NaickerS, et al.; Conference Participants: Kidney disease in the setting of HIV infection: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int93: 545–559, 2018PubMed
SwanepoelCR, AttaMG, D’AgatiVD, EstrellaMM, FogoAB, NaickerS, ; Conference Participants: Kidney disease in the setting of HIV infection: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 93: 545–559, 2018PubMed)| false
RaoTK, FilipponeEJ, NicastriAD, LandesmanSH, FrankE, ChenCK, et al.: Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med310: 669–673, 1984PubMed
RaoTK, FilipponeEJ, NicastriAD, LandesmanSH, FrankE, ChenCK, : Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 310: 669–673, 1984PubMed)| false
WinstonJA, BruggemanLA, RossMD, JacobsonJ, RossL, D’AgatiVD, et al.: Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med344: 1979–1984, 2001PubMed
WinstonJA, BruggemanLA, RossMD, JacobsonJ, RossL, D’AgatiVD, : Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 344: 1979–1984, 2001PubMed)| false
BruggemanLA, DikmanS, MengC, QuagginSE, CoffmanTM, KlotmanPE: Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest100: 84–92, 1997PubMed
PapetaN, KirylukK, PatelA, SterkenR, KacakN, SnyderHJ, et al.: APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol22: 1991–1996, 2011PubMed
PapetaN, KirylukK, PatelA, SterkenR, KacakN, SnyderHJ, : APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol 22: 1991–1996, 2011PubMed)| false
AttaMG, EstrellaMM, SkoreckiKL, KoppJB, WinklerCA, WasserWG, et al.: Association of APOL1 genotype with renal histology among Black HIV-positive patients undergoing kidney biopsy. Clin J Am Soc Nephrol11: 262–270, 2016PubMed
AttaMG, EstrellaMM, SkoreckiKL, KoppJB, WinklerCA, WasserWG, : Association of APOL1 genotype with renal histology among Black HIV-positive patients undergoing kidney biopsy. Clin J Am Soc Nephrol 11: 262–270, 2016PubMed)| false
KasembeliAN, DuarteR, RamsayM, MosianeP, DickensC, Dix-PeekT, et al.: APOL1 risk variants are strongly associated with HIV-associated nephropathy in Black South Africans. J Am Soc Nephrol26: 2882–2890, 2015PubMed
KasembeliAN, DuarteR, RamsayM, MosianeP, DickensC, Dix-PeekT, : APOL1 risk variants are strongly associated with HIV-associated nephropathy in Black South Africans. J Am Soc Nephrol 26: 2882–2890, 2015PubMed)| false
EstrellaMM, LiM, TinA, AbrahamAG, ShlipakMG, PenugondaS, et al.: The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status. Clin Infect Dis60: 646–652, 2015PubMed
EstrellaMM, LiM, TinA, AbrahamAG, ShlipakMG, PenugondaS, : The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status. Clin Infect Dis 60: 646–652, 2015PubMed)| false
AttaMG, EstrellaMM, KupermanM, FoyMC, FineDM, RacusenLC, et al.: HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics. Kidney Int82: 338–343, 2012PubMed
AttaMG, EstrellaMM, KupermanM, FoyMC, FineDM, RacusenLC, : HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics. Kidney Int 82: 338–343, 2012PubMed)| false
KudoseS, SantorielloD, BombackAS, StokesMB, BatalI, MarkowitzGS, et al.: The spectrum of kidney biopsy findings in HIV-infected patients in the modern era. Kidney Int97: 1006–1016, 2020PubMed
KudoseS, SantorielloD, BombackAS, StokesMB, BatalI, MarkowitzGS, : The spectrum of kidney biopsy findings in HIV-infected patients in the modern era. Kidney Int 97: 1006–1016, 2020PubMed)| false
LucasGM, RossMJ, StockPG, ShlipakMG, WyattCM, GuptaSK, et al.; HIV Medicine Association of the Infectious Diseases Society of America: Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis59: e96–e138, 2014PubMed
LucasGM, RossMJ, StockPG, ShlipakMG, WyattCM, GuptaSK, ; HIV Medicine Association of the Infectious Diseases Society of America: Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 59: e96–e138, 2014PubMed)| false
GuptaSK, PostFA, ArribasJR, EronJJJr, WohlDA, ClarkeAE, et al.: Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: A pooled analysis of 26 clinical trials. AIDS33: 1455–1465, 2019PubMed
GuptaSK, PostFA, ArribasJR, EronJJJr, WohlDA, ClarkeAE, : Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: A pooled analysis of 26 clinical trials. AIDS 33: 1455–1465, 2019PubMed)| false
SawinskiD, FordeKA, LockeJE, CohenJB, WeldonJ, ShultsJ, et al.: Race but not hepatitis C co-infection affects survival of HIV+ individuals on dialysis in contemporary practice. Kidney Int93: 706–715, 2018PubMed
SawinskiD, FordeKA, LockeJE, CohenJB, WeldonJ, ShultsJ, : Race but not hepatitis C co-infection affects survival of HIV+ individuals on dialysis in contemporary practice. Kidney Int 93: 706–715, 2018PubMed)| false
LockeJE, MehtaS, ReedRD, MacLennanP, MassieA, NelloreA, et al.: A national study of outcomes among HIV-infected kidney transplant recipients. J Am Soc Nephrol26: 2222–2229, 2015PubMed
LockeJE, MehtaS, ReedRD, MacLennanP, MassieA, NelloreA, : A national study of outcomes among HIV-infected kidney transplant recipients. J Am Soc Nephrol 26: 2222–2229, 2015PubMed)| false
LockeJE, GustafsonS, MehtaS, ReedRD, SheltonB, MacLennanPA, et al.: Survival benefit of kidney transplantation in HIV-infected patients. Ann Surg265: 604–608, 2017PubMed
MullerE, BardayZ, MendelsonM, KahnD: HIV-positive-to-HIV-positive kidney transplantation--results at 3 to 5 years. N Engl J Med372: 613–620, 2015PubMed
MullerE, BardayZ, MendelsonM, KahnD: HIV-positive-to-HIV-positive kidney transplantation--results at 3 to 5 years. N Engl J Med 372: 613–620, 2015PubMed)| false
CharuV, AndeenN, WalavalkarV, LapasiaJ, KimJY, LinA, et al.: Membranous nephropathy in patients with HIV: A report of 11 cases. BMC Nephrol21: 401, 2020PubMed
HaasM, KaulS, EustaceJA: HIV-associated immune complex glomerulonephritis with “lupus-like” features: A clinicopathologic study of 14 cases. Kidney Int67: 1381–1390, 2005PubMed
HaasM, KaulS, EustaceJA: HIV-associated immune complex glomerulonephritis with “lupus-like” features: A clinicopathologic study of 14 cases. Kidney Int 67: 1381–1390, 2005PubMed)| false
FoyMC, EstrellaMM, LucasGM, TahirF, FineDM, MooreRD, et al.: Comparison of risk factors and outcomes in HIV immune complex kidney disease and HIV-associated nephropathy. Clin J Am Soc Nephrol8: 1524–1532, 2013PubMed
World Health Organization: Hepatitis C. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c#:∼:text=Globally%2C%20an%20estimated%2058%20million,carcinoma%20(primary%20liver%20cancer.). Accessed June 14, 2022)| false
CicardiM, CesanaB, Del NinnoE, PappalardoE, SiliniE, AgostoniA, et al.: Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C. J Viral Hepat7: 138–143, 2000PubMed
CicardiM, CesanaB, Del NinnoE, PappalardoE, SiliniE, AgostoniA, : Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C. J Viral Hepat 7: 138–143, 2000PubMed)| false
RutledgeSM, ChungRT, SiseME: Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis. Hemodial Int22[Suppl 1]: S81–S96, 2018PubMed
RutledgeSM, ChungRT, SiseME: Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis. Hemodial Int 22[Suppl 1]: S81–S96, 2018PubMed)| false
TrejoO, Ramos-CasalsM, García-CarrascoM, YagüeJ, JiménezS, de la RedG, et al.: Cryoglobulinemia: Study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore)80: 252–262, 2001PubMed
TrejoO, Ramos-CasalsM, García-CarrascoM, YagüeJ, JiménezS, de la RedG, : Cryoglobulinemia: Study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) 80: 252–262, 2001PubMed)| false
Kidney Disease: Improving Global Outcomes CKD-MBD Update Work Group: KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011) 7: 1–59, 2017.
Kidney Disease: Improving Global Outcomes CKD-MBD Update Work Group: KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011) 7: 1–59, 2017.)| false
SaadounD, PolS, FerfarY, AlricL, HezodeC, Si AhmedSN, et al.: Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterology153: 49–52.e5, 2017PubMed
SaadounD, PolS, FerfarY, AlricL, HezodeC, Si AhmedSN, : Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterology 153: 49–52.e5, 2017PubMed)| false
EmeryJS, KuczynskiM, LaD, AlmarzooqiS, KowgierM, ShahH, et al.: Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia. Am J Gastroenterol112: 1298–1308, 2017PubMed
EmeryJS, KuczynskiM, LaD, AlmarzooqiS, KowgierM, ShahH, : Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia. Am J Gastroenterol 112: 1298–1308, 2017PubMed)| false
GragnaniL, PilusoA, UrraroT, FabbrizziA, FognaniE, PetracciaL, et al.: Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: Preliminary results of a prospective pilot study. Curr Drug Targets18: 772–785, 2017PubMed
GragnaniL, PilusoA, UrraroT, FabbrizziA, FognaniE, PetracciaL, : Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: Preliminary results of a prospective pilot study. Curr Drug Targets 18: 772–785, 2017PubMed)| false
JadoulM, BerenguerMC, DossW, FabriziF, IzopetJ, JhaV, et al.: Executive summary of the 2018 KDIGO hepatitis C in CKD guideline: Welcoming advances in evaluation and management. Kidney Int94: 663–673, 2018PubMed
JadoulM, BerenguerMC, DossW, FabriziF, IzopetJ, JhaV, : Executive summary of the 2018 KDIGO hepatitis C in CKD guideline: Welcoming advances in evaluation and management. Kidney Int 94: 663–673, 2018PubMed)| false
Kidney Disease: Improving Global Outcomes (KDIGO): KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl (109): S1–S99, 2008PubMed
Kidney Disease: Improving Global Outcomes (KDIGO): KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl (109): S1–S99, 2008PubMed)| false
MisianiR, BellavitaP, FeniliD, VicariO, MarchesiD, SironiPL, et al.: Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med330: 751–756, 1994PubMed
MisianiR, BellavitaP, FeniliD, VicariO, MarchesiD, SironiPL, : Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 330: 751–756, 1994PubMed)| false
CasatoM, AgnelloV, PucilloLP, KnightGB, LeoniM, Del VecchioS, et al.: Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood90: 3865–3873, 1997PubMed
CasatoM, AgnelloV, PucilloLP, KnightGB, LeoniM, Del VecchioS, : Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 90: 3865–3873, 1997PubMed)| false
MazzaroC, ZoratF, CaizziM, DonadaC, Di GennaroG, MasoLD, et al.: Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: A pilot study. J Hepatol42: 632–638, 2005PubMed
MazzaroC, ZoratF, CaizziM, DonadaC, Di GennaroG, MasoLD, : Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: A pilot study. J Hepatol 42: 632–638, 2005PubMed)| false
HadziyannisSJ, SetteHJr, MorganTR, BalanV, DiagoM, MarcellinP, et al.; PEGASYS International Study Group: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med140: 346–355, 2004PubMed
HadziyannisSJ, SetteHJr, MorganTR, BalanV, DiagoM, MarcellinP, ; PEGASYS International Study Group: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346–355, 2004PubMed)| false
CacoubP, LidoveO, MaisonobeT, DuhautP, ThibaultV, GhillaniP, et al.: Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum46: 3317–3326, 2002PubMed
DammaccoF, TucciFA, LaulettaG, GattiP, De ReV, ConteducaV, et al.: Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: A long-term study. Blood116: 343–353, 2010PubMed
QuartuccioL, SoardoG, RomanoG, ZajaF, ScottCA, De MarchiG, et al.: Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: Efficacy and safety in the absence of steroids. Rheumatology (Oxford)45: 842–846, 2006PubMed
QuartuccioL, SoardoG, RomanoG, ZajaF, ScottCA, De MarchiG, : Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: Efficacy and safety in the absence of steroids. Rheumatology (Oxford) 45: 842–846, 2006PubMed)| false
SansonnoD, De ReV, LaulettaG, TucciFA, BoiocchiM, DammaccoF: Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood101: 3818–3826, 2003PubMed
SansonnoD, De ReV, LaulettaG, TucciFA, BoiocchiM, DammaccoF: Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101: 3818–3826, 2003PubMed)| false
De VitaS, QuartuccioL, IsolaM, MazzaroC, ScainiP, LenziM, et al.: A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum64: 843–853, 2012PubMed
De VitaS, QuartuccioL, IsolaM, MazzaroC, ScainiP, LenziM, : A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 64: 843–853, 2012PubMed)| false
SnellerMC, HuZ, LangfordCA: A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum64: 835–842, 2012PubMed
SnellerMC, HuZ, LangfordCA: A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 64: 835–842, 2012PubMed)| false
SaadounD, ThibaultV, Si AhmedSN, AlricL, MalletM, GuillaudC, et al.: Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis75: 1777–1782, 2016PubMed
GragnaniL, VisentiniM, FognaniE, UrraroT, De SantisA, PetracciaL, et al.: Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology64: 1473–1482, 2016PubMed
GragnaniL, VisentiniM, FognaniE, UrraroT, De SantisA, PetracciaL, : Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology 64: 1473–1482, 2016PubMed)| false
MauroE, QuartuccioL, GhersettiM, LenziM, GittoS, AndreoneP, et al.: Direct acting antiviral (DAA) therapy of HCV, effects on the cryoglobulinemic vasculitis: A multi center open label study. Dig Liver Dis49: e32, 2017
MauroE, QuartuccioL, GhersettiM, LenziM, GittoS, AndreoneP, : Direct acting antiviral (DAA) therapy of HCV, effects on the cryoglobulinemic vasculitis: A multi center open label study. Dig Liver Dis 49: e32, 2017)| false
CerretelliG, GragnaniL, MontiM, ArenaU, FognaniE, PetracciaL, et al.: Sofosbuvir/ribavirin treatment in patients with genotype 2, hepatitis C virus infection and symptomatic mixed cryoglobulinemia: An interim analysis on safety, efficacy and impact on quality of life. J Hepatol66: S505, 2017
CerretelliG, GragnaniL, MontiM, ArenaU, FognaniE, PetracciaL, : Sofosbuvir/ribavirin treatment in patients with genotype 2, hepatitis C virus infection and symptomatic mixed cryoglobulinemia: An interim analysis on safety, efficacy and impact on quality of life. J Hepatol 66: S505, 2017)| false
MiailhesP, Hartig-LavieK, VirlogeuxV, et al.: Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia. Clin Microbiol Infect24: 1215.e1–1215.e4, 201810.1016/j.cmi.2018.05.019
MiailhesP, Hartig-LavieK, VirlogeuxV, : Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia. Clin Microbiol Infect 24: 1215.e1–1215.e4, 201810.1016/j.cmi.2018.05.019)| false
BonacciM, LensS, LondoñoMC, MariñoZ, CidMC, Ramos-CasalsM, et al.: Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol15: 575–583.e1, 2017PubMed
ComarmondC, CacoubP, SaadounD: Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals. Therap Adv Gastroenterol13: 1756284820942617, 2020PubMed
ComarmondC, CacoubP, SaadounD: Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals. Therap Adv Gastroenterol 13: 1756284820942617, 2020PubMed)| false
RothD, NelsonDR, BruchfeldA, LiapakisA, SilvaM, MonsourHJr, et al.: Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): A combination phase 3 study. Lancet386: 1537–1545, 2015PubMed
GaneE, LawitzE, PugatchD, PapatheodoridisG, BräuN, BrownA, et al.: Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med377: 1448–1455, 2017PubMed
GaneE, LawitzE, PugatchD, PapatheodoridisG, BräuN, BrownA, : Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 377: 1448–1455, 2017PubMed)| false
LawitzE, FlisiakR, AbunimehM, SiseME, ParkJY, KaskasM, et al.: Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. Liver Int40: 1032–1041, 2020PubMed
SiseME, ChuteDF, OppongY, DavisMI, LongJD, SilvaST, et al.: Direct-acting antiviral therapy slows kidney function decline in patients with hepatitis C virus infection and chronic kidney disease. Kidney Int97: 193–201, 2020PubMed
FayedA, El NokeetyMM, Samy AbdelazizT, SamirHH, HamzaWM, El ShabonyT: Incidence and characteristics of de novo renal cryoglobulinemia after direct-acting antivirals treatment in an Egyptian hepatitis C cohort. Nephron140: 275–281, 2018PubMed
FayedA, El NokeetyMM, Samy AbdelazizT, SamirHH, HamzaWM, El ShabonyT: Incidence and characteristics of de novo renal cryoglobulinemia after direct-acting antivirals treatment in an Egyptian hepatitis C cohort. Nephron 140: 275–281, 2018PubMed)| false
HoganJJ, LimMA, PalmerMB, BloomRD, ChungRT, SiseME: Development of proteinuria and focal segmental glomerulosclerosis during direct-acting antiviral therapy for hepatitis C virus infection. Hepatology66: 658–660, 2017PubMed
HoganJJ, LimMA, PalmerMB, BloomRD, ChungRT, SiseME: Development of proteinuria and focal segmental glomerulosclerosis during direct-acting antiviral therapy for hepatitis C virus infection. Hepatology 66: 658–660, 2017PubMed)| false
MarkowitzGS, ChengJT, ColvinRB, TrebbinWM, D’AgatiVD: Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol9: 2244–2252, 1998PubMed
MarkowitzGS, ChengJT, ColvinRB, TrebbinWM, D’AgatiVD: Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol 9: 2244–2252, 1998PubMed)| false
NasrSH, ValeriAM, CornellLD, FidlerME, SethiS, LeungN, et al.: Fibrillary glomerulonephritis: A report of 66 cases from a single institution. Clin J Am Soc Nephrol6: 775–784, 2011PubMed
NasrSH, ValeriAM, CornellLD, FidlerME, SethiS, LeungN, : Fibrillary glomerulonephritis: A report of 66 cases from a single institution. Clin J Am Soc Nephrol 6: 775–784, 2011PubMed)| false
JiF, LiZ, GeH, DengH: Successful interferon-α treatment in a patient with IgA nephropathy associated with hepatitis C virus infection. Intern Med49: 2531–2532, 2010PubMed
JiF, LiZ, GeH, DengH: Successful interferon-α treatment in a patient with IgA nephropathy associated with hepatitis C virus infection. Intern Med 49: 2531–2532, 2010PubMed)| false
World Health Organization: Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Available at: https://www.who.int/publications/i/item/9789240027077. Accessed June 14, 2022)| false
CombesB, ShoreyJ, BarreraA, StastnyP, EigenbrodtEH, HullAR, et al.: Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet2: 234–237, 1971PubMed
LaiKN, LiPK, LuiSF, AuTC, TamJS, TongKL, : Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 324: 1457–1463, 1991PubMed)| false
MoonJY, LeeSH: Treatment of hepatitis B virus-associated membranous nephropathy: Lamivudine era versus post-lamivudine era. Korean J Intern Med (Korean Assoc Intern Med)27: 394–396, 2012PubMed
MoonJY, LeeSH: Treatment of hepatitis B virus-associated membranous nephropathy: Lamivudine era versus post-lamivudine era. Korean J Intern Med (Korean Assoc Intern Med) 27: 394–396, 2012PubMed)| false
ConjeevaramHS, HoofnagleJH, AustinHA, ParkY, FriedMW, Di BisceglieAM: Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology109: 540–546, 1995PubMed
ConjeevaramHS, HoofnagleJH, AustinHA, ParkY, FriedMW, Di BisceglieAM: Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology 109: 540–546, 1995PubMed)| false
ChungDR, YangWS, KimSB, YuE, ChungYH, LeeY, et al.: Treatment of hepatitis B virus associated glomerulonephritis with recombinant human alpha interferon. Am J Nephrol17: 112–117, 1997PubMed
ChangTT, GishRG, de ManR, GadanoA, SollanoJ, ChaoYC, et al.; BEHoLD AI463022 Study Group: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med354: 1001–1010, 2006PubMed
ChangTT, GishRG, de ManR, GadanoA, SollanoJ, ChaoYC, ; BEHoLD AI463022 Study Group: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354: 1001–1010, 2006PubMed)| false
WangL, YeZ, LiangH, ZhangB, XuL, FengZ, et al.: The combination of tacrolimus and entecavir improves the remission of HBV-associated glomerulonephritis without enhancing viral replication. Am J Transl Res8: 1593–1600, 2016PubMed
WangL, YeZ, LiangH, ZhangB, XuL, FengZ, : The combination of tacrolimus and entecavir improves the remission of HBV-associated glomerulonephritis without enhancing viral replication. Am J Transl Res 8: 1593–1600, 2016PubMed)| false
LaiKN, TamJS, LinHJ, LaiFM: The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron54: 12–17, 1990PubMed
LaiKN, TamJS, LinHJ, LaiFM: The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron 54: 12–17, 1990PubMed)| false
LaiFM, TamJS, LiPK, LaiKN: Replication of hepatitis B virus with corticosteroid therapy in hepatitis B virus related membranous nephropathy. Virchows Arch A Pathol Anat Histopathol414: 279–284, 1989PubMed
LaiFM, TamJS, LiPK, LaiKN: Replication of hepatitis B virus with corticosteroid therapy in hepatitis B virus related membranous nephropathy. Virchows Arch A Pathol Anat Histopathol 414: 279–284, 1989PubMed)| false
MichalakT: Immune complexes of hepatitis B surface antigen in the pathogenesis of periarteritis nodosa. A study of seven necropsy cases. Am J Pathol90: 619–632, 1978PubMed
MichalakT: Immune complexes of hepatitis B surface antigen in the pathogenesis of periarteritis nodosa. A study of seven necropsy cases. Am J Pathol 90: 619–632, 1978PubMed)| false
LaiKN, LaiFM: Clinical features and the natural course of hepatitis B virus-related glomerulopathy in adults. Kidney Int Suppl 35: S40–S45, 1991PubMed)| false
TrepoC, GuillevinL: Polyarteritis nodosa and extrahepatic manifestations of HBV infection: The case against autoimmune intervention in pathogenesis. J Autoimmun16: 269–274, 2001PubMed
TrepoC, GuillevinL: Polyarteritis nodosa and extrahepatic manifestations of HBV infection: The case against autoimmune intervention in pathogenesis. J Autoimmun 16: 269–274, 2001PubMed)| false
GuillevinL, LhoteF, CohenP, SauvagetF, JarrousseB, LortholaryO, et al.: Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore)74: 238–253, 1995PubMed
GuillevinL, LhoteF, CohenP, SauvagetF, JarrousseB, LortholaryO, : Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 74: 238–253, 1995PubMed)| false
PagnouxC, SerorR, HenegarC, MahrA, CohenP, Le GuernV, et al.; French Vasculitis Study Group: Clinical features and outcomes in 348 patients with polyarteritis nodosa: A systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group database. Arthritis Rheum62: 616–626, 2010PubMed
PagnouxC, SerorR, HenegarC, MahrA, CohenP, Le GuernV, ; French Vasculitis Study Group: Clinical features and outcomes in 348 patients with polyarteritis nodosa: A systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group database. Arthritis Rheum 62: 616–626, 2010PubMed)| false
GuillevinL, MahrA, CallardP, GodmerP, PagnouxC, LerayE, et al.; French Vasculitis Study Group: Hepatitis B virus-associated polyarteritis nodosa: Clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore)84: 313–322, 2005PubMed
GuillevinL, MahrA, CallardP, GodmerP, PagnouxC, LerayE, ; French Vasculitis Study Group: Hepatitis B virus-associated polyarteritis nodosa: Clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 84: 313–322, 2005PubMed)| false
MukhtyarC, GuillevinL, CidMC, DasguptaB, de GrootK, GrossW, et al.; European Vasculitis Study Group: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis68: 310–317, 2009PubMed
MukhtyarC, GuillevinL, CidMC, DasguptaB, de GrootK, GrossW, ; European Vasculitis Study Group: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68: 310–317, 2009PubMed)| false
SunIO, HongYA, ParkHS, ChoiSR, ChungBH, ParkCW, et al.: Clinical characteristics and treatment of patients with IgA nephropathy and hepatitis B surface antigen. Ren Fail35: 446–451, 2013PubMed
SunIO, HongYA, ParkHS, ChoiSR, ChungBH, ParkCW, : Clinical characteristics and treatment of patients with IgA nephropathy and hepatitis B surface antigen. Ren Fail 35: 446–451, 2013PubMed)| false
ZhouTB, JiangZP: Is there an association of hepatitis B virus infection with minimal change disease of nephrotic syndrome? A clinical observational report. Ren Fail37: 459–461, 2015PubMed
ZhouTB, JiangZP: Is there an association of hepatitis B virus infection with minimal change disease of nephrotic syndrome? A clinical observational report. Ren Fail 37: 459–461, 2015PubMed)| false
GuptaS, HayekSS, WangW, ChanL, MathewsKS, MelamedML, et al.; STOP-COVID Investigators: Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med180: 1436–1447, 2020PubMed
GuptaS, HayekSS, WangW, ChanL, MathewsKS, MelamedML, ; STOP-COVID Investigators: Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med 180: 1436–1447, 2020PubMed)| false
MayRM, CassolC, HannoudiA, LarsenCP, LermaEV, HaunRS, et al.: A multi-center retrospective cohort study defines the spectrum of kidney pathology in coronavirus 2019 disease (COVID-19). Kidney Int100: 1303–1315, 2021PubMed
MayRM, CassolC, HannoudiA, LarsenCP, LermaEV, HaunRS, : A multi-center retrospective cohort study defines the spectrum of kidney pathology in coronavirus 2019 disease (COVID-19). Kidney Int 100: 1303–1315, 2021PubMed)| false
WuH, LarsenCP, Hernandez-ArroyoCF, MohamedMMB, CazaT, SharshirM, et al.: AKI and collapsing glomerulopathy associated with COVID-19 and APOL 1 high-risk genotype. J Am Soc Nephrol31: 1688–1695, 2020PubMed
HasslerL, ReyesF, SparksMA, WellingP, BatlleD: Evidence for and against direct kidney infection by SARS-CoV-2 in patients with COVID-19. Clin J Am Soc Nephrol16: 1755–1765, 2021PubMed
HasslerL, ReyesF, SparksMA, WellingP, BatlleD: Evidence for and against direct kidney infection by SARS-CoV-2 in patients with COVID-19. Clin J Am Soc Nephrol 16: 1755–1765, 2021PubMed)| false
SuH, YangM, WanC, YiL-X, TangF, ZhuH-Y, et al.: Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int98: 219–227, 2020PubMed
NasrSH, MarkowitzGS, StokesMB, SaidSM, ValeriAM, D’AgatiVD: Acute postinfectious glomerulonephritis in the modern era: Experience with 86 adults and review of the literature. Medicine (Baltimore)87: 21–32, 2008PubMed
NasrSH, MarkowitzGS, StokesMB, SaidSM, ValeriAM, D’AgatiVD: Acute postinfectious glomerulonephritis in the modern era: Experience with 86 adults and review of the literature. Medicine (Baltimore) 87: 21–32, 2008PubMed)| false
ShimizuY, SakuraiH, HirayamaK, SekiM, YohK, YamagataK, et al.: Staphylococcal cell membrane antigen, a possible antigen in post-methicillin resistant Staphylococcus aureus (MRSA) infection nephritis and IgA nephropathy, exhibits high immunogenic activity that is enhanced by superantigen. J Nephrol18: 249–256, 2005PubMed
ShimizuY, SakuraiH, HirayamaK, SekiM, YohK, YamagataK, : Staphylococcal cell membrane antigen, a possible antigen in post-methicillin resistant Staphylococcus aureus (MRSA) infection nephritis and IgA nephropathy, exhibits high immunogenic activity that is enhanced by superantigen. J Nephrol 18: 249–256, 2005PubMed)| false
NasrSH, FidlerME, ValeriAM, CornellLD, SethiS, ZollerA, et al.: Postinfectious glomerulonephritis in the elderly. J Am Soc Nephrol22: 187–195, 2011PubMed
SatoskarAA, SuleimanS, AyoubI, HemmingerJ, ParikhS, BrodskySV, et al.: Staphylococcus infection-associated GN - Spectrum of IgA staining and prevalence of ANCA in a single-center cohort. Clin J Am Soc Nephrol12: 39–49, 2017PubMed
SatoskarAA, SuleimanS, AyoubI, HemmingerJ, ParikhS, BrodskySV, : Staphylococcus infection-associated GN - Spectrum of IgA staining and prevalence of ANCA in a single-center cohort. Clin J Am Soc Nephrol 12: 39–49, 2017PubMed)| false
MontsenyJJ, MeyrierA, KleinknechtD, CallardP: The current spectrum of infectious glomerulonephritis. Experience with 76 patients and review of the literature. Medicine (Baltimore)74: 63–73, 1995PubMed
MontsenyJJ, MeyrierA, KleinknechtD, CallardP: The current spectrum of infectious glomerulonephritis. Experience with 76 patients and review of the literature. Medicine (Baltimore) 74: 63–73, 1995PubMed)| false
BatsfordSR, MezzanoS, MihatschM, SchiltzE, Rodríguez-IturbeB: Is the nephritogenic antigen in post-streptococcal glomerulonephritis pyrogenic exotoxin B (SPE B) or GAPDH?Kidney Int68: 1120–1129, 2005PubMed
BatsfordSR, MezzanoS, MihatschM, SchiltzE, Rodríguez-IturbeB: Is the nephritogenic antigen in post-streptococcal glomerulonephritis pyrogenic exotoxin B (SPE B) or GAPDH?Kidney Int 68: 1120–1129, 2005PubMed)| false
Rodríguez-IturbeB, BatsfordS: Pathogenesis of poststreptococcal glomerulonephritis a century after Clemens von Pirquet. Kidney Int71: 1094–1104, 2007PubMed
Rodríguez-IturbeB, BatsfordS: Pathogenesis of poststreptococcal glomerulonephritis a century after Clemens von Pirquet. Kidney Int 71: 1094–1104, 2007PubMed)| false
SorgerK, BalunJ, HübnerFK, KöhlerH, OlbingH, SchulzW, et al.: The garland type of acute postinfectious glomerulonephritis: Morphological characteristics and follow-up studies. Clin Nephrol20: 17–26, 1983PubMed
SorgerK, GesslerM, HübnerFK, KöhlerH, OlbingH, SchulzW, et al.: Follow-up studies of three subtypes of acute postinfectious glomerulonephritis ascertained by renal biopsy. Clin Nephrol27: 111–124, 1987PubMed
JohnstonF, CarapetisJ, PatelMS, WallaceT, SpillaneP: Evaluating the use of penicillin to control outbreaks of acute poststreptococcal glomerulonephritis. Pediatr Infect Dis J18: 327–332, 1999PubMed
JohnstonF, CarapetisJ, PatelMS, WallaceT, SpillaneP: Evaluating the use of penicillin to control outbreaks of acute poststreptococcal glomerulonephritis. Pediatr Infect Dis J 18: 327–332, 1999PubMed)| false
SethiS, FervenzaFC, ZhangY, ZandL, MeyerNC, BorsaN, et al.: Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int83: 293–299, 2013PubMed
SethiS, FervenzaFC, ZhangY, ZandL, MeyerNC, BorsaN, : Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int 83: 293–299, 2013PubMed)| false
ChauvetS, BerthaudR, DevrieseM, MignotetM, Vieira MartinsP, Robe-RybkineT, et al.: Anti-factor B antibodies and acute postinfectious GN in children. J Am Soc Nephrol31: 829–840, 2020PubMed
ChauvetS, BerthaudR, DevrieseM, MignotetM, Vieira MartinsP, Robe-RybkineT, : Anti-factor B antibodies and acute postinfectious GN in children. J Am Soc Nephrol 31: 829–840, 2020PubMed)| false
GambleCN, ReardanJB: Immunopathogenesis of syphilitic glomerulonephritis. Elution of antitreponemal antibody from glomerular immune-complex deposits. N Engl J Med292: 449–454, 1975PubMed
GambleCN, ReardanJB: Immunopathogenesis of syphilitic glomerulonephritis. Elution of antitreponemal antibody from glomerular immune-complex deposits. N Engl J Med 292: 449–454, 1975PubMed)| false
Hoshino-ShimizuS, De BritoT, KanamuraHY, CantoAL, SilvaAO, CamposAR, et al.: Human schistosomiasis: Schistosoma mansoni antigen detection in renal glomeruli. Trans R Soc Trop Med Hyg70: 492–496, 1976PubMed
Hoshino-ShimizuS, De BritoT, KanamuraHY, CantoAL, SilvaAO, CamposAR, : Human schistosomiasis: Schistosoma mansoni antigen detection in renal glomeruli. Trans R Soc Trop Med Hyg 70: 492–496, 1976PubMed)| false
Ali-KhanZ, RauschRL: Demonstration of amyloid and immune complex deposits in renal and hepatic parenchyma of Alaskan alveolar hydatid disease patients. Ann Trop Med Parasitol81: 381–392, 1987PubMed
Ali-KhanZ, RauschRL: Demonstration of amyloid and immune complex deposits in renal and hepatic parenchyma of Alaskan alveolar hydatid disease patients. Ann Trop Med Parasitol 81: 381–392, 1987PubMed)| false